AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16928841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 37
Study 16928841 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH)
Number of subjects: 37
Study 16928841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study 15288411 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150-225 mg
Number of subjects: 244
Study 15288411 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 244
Study 15288411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 11565622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 108
Study 11565622 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 108
Study 9629818 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-prosecutory enforcement of public health legislation (intervention)
Number of subjects: 12502
Study 9629818 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12502
Study 8162464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam for 14 days
Number of subjects: 73
Study 8162464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8162464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 73
Study 3466563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 56
Study 3466563 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole plus colistin
Number of subjects: 56
Study 31032881 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated stopping of trials before reaching planned sample size
Number of subjects: 0
Study 31032881 — intervention group
Group type: COMPARATOR
Intervention: Control group from RCTs (not specified)
Number of subjects: 0
Study 28689453 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF (elvitegravir, cobicistat, emtricitabine, and tenofovir DF)
Number of subjects: 433
Study 28689453 — intervention group
Group type: COMPARATOR
Intervention: NNRTI + FTC/TDF (no-switch)
Number of subjects: 433
Study 28689453 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Number of subjects: 433
Study 26537218 — intervention group
Group type: EXPERIMENTAL
Intervention: High PL krill oil (3 g/day)
Number of subjects: 20
Study 26537218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PL krill oil (1.5 g/day)
Number of subjects: 20
Study 26537218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 20
Study 23337231 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Use Log (RUL)
Number of subjects: 85
Study 23337231 — intervention group
Group type: COMPARATOR
Intervention: No Resource Use Log (Control)
Number of subjects: 85
Study 21168198 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/m2 daily for 5 days every 21 days (regimen I)
Number of subjects: 81
Study 21168198 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 4.0 mg/m2/day on days 1, 8, and 15 of a 28-day cycle (regimen II)
Number of subjects: 81
Study 19675193 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 83
Study 17348888 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tooth implants
Number of subjects: 62
Study 17348888 — intervention group
Group type: COMPARATOR
Intervention: Natural tooth
Number of subjects: 62
Study 17348888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraindividual comparison (implant vs natural tooth)
Number of subjects: 62
Study 14977817 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 216
Study 14977817 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 216
Study 14977817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of gefitinib combined
Number of subjects: 216
Study 14977817 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 or 500 mg daily)
Number of subjects: 216
Study 14977817 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 216
Study 11673773 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (35% of energy)
Number of subjects: 101
Study 11673773 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy)
Number of subjects: 101
Study 9134944 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/d of vitamin E
Number of subjects: 88
Study 9134944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 9134944 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d of vitamin E
Number of subjects: 88
Study 9134944 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/d of vitamin E
Number of subjects: 88
Study 9134944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 88
Study 7631080 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 27
Study 7631080 — intervention group
Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 27
Study 2979270 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg o.m.)
Number of subjects: 152
Study 2979270 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 152
Study 28846200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Flute (LF)
Number of subjects: 64
Study 28846200 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline inhalation (HSI)
Number of subjects: 64
Study 28846200 — intervention group
Group type: COMPARATOR
Intervention: No induction
Number of subjects: 64
Study 26954966 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke care pathway (CP)
Number of subjects: 162
Study 26954966 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 162
Study 23456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (motivational materials and small-group instruction)
Number of subjects: 1196
Study 23456902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 1196
Study 23456902 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1196
Study 23456902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1196
Study 23297638 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics of a wide spectrum of action
Number of subjects: 110
Study 20545993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg per day for 3 months)
Number of subjects: 92
Study 20545993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg per day for 3 months)
Number of subjects: 92
Study 20545993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 92
Study 18677234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (GrA): 15 min WC application without reheating
Number of subjects: 32
Study 18677234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (GrB): 30 min WC application with reheating every 2 min
Number of subjects: 32
Study 18677234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (GrC): 30 min WC application optimizing contact with the lower lid and reheating every 2 min
Number of subjects: 32
Study 15856233 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m(2) followed by Carboplatin AUC 7
Number of subjects: 46
Study 15856233 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m(2) followed by Carboplatin AUC 6
Number of subjects: 46
Study 12067917 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg/kg FFR‐rFVIIa and 40 to 50 U/kg heparin
Number of subjects: 24
Study 12067917 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/kg FFR‐rFVIIa and 100 U/kg heparin
Number of subjects: 24
Study 12067917 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/kg FFR‐rFVIIa and 100 U/kg heparin
Number of subjects: 24
Study 10588300 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2022
Study 10588300 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2022
Study 8724292 — intervention group
Group type: EXPERIMENTAL
Intervention: pANCA+ patients
Number of subjects: 385
Study 8724292 — intervention group
Group type: COMPARATOR
Intervention: pANCA- patients
Number of subjects: 385
Study 1549928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray 200 mg
Number of subjects: 24
Study 1549928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 4040338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 0
Study 4040338 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy
Number of subjects: 0
Study 4040338 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy and myringotomy
Number of subjects: 0
Study 4040338 — intervention group
Group type: COMPARATOR
Intervention: Combination of adenoidectomy and tympanostomy tubes
Number of subjects: 0
Study 31464525 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 0
Study 29679586 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscope (VL)
Number of subjects: 78
Study 29679586 — intervention group
Group type: COMPARATOR
Intervention: Macintosh Laryngoscope (ML)
Number of subjects: 78
Study 24666696 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐705498 (600 mg)
Number of subjects: 21
Study 24666696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23082701 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 138
Study 23082701 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 138
Study 20453006 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional regulator III (FR‐3) treatment
Number of subjects: 15
Study 20453006 — intervention group
Group type: COMPARATOR
Intervention: Control group (Class I malocclusion)
Number of subjects: 15
Study 17336790 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week psychoeducational intervention
Number of subjects: 24
Study 17336790 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring control (SMC) group
Number of subjects: 24
Study 16340712 — intervention group
Group type: EXPERIMENTAL
Intervention: Education regarding back therapy and pain management combined with three consecutive days of topical heat therapy (104 degrees F or 40 degrees C for 8 hours)
Number of subjects: 43
Study 16340712 — intervention group
Group type: COMPARATOR
Intervention: Education regarding back therapy and pain management alone
Number of subjects: 43
Study 12081835 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements (1 mg x kg(‐1) x d(‐1)) from 4 to 9 mo of age
Number of subjects: 25
Study 12081835 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo from 4 to 6 mo and iron supplements from 6 to 9 mo
Number of subjects: 25
Study 12081835 — intervention group
Group type: COMPARATOR
Intervention: Placebo from 4 to 9 mo
Number of subjects: 25
Study 9873848 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV protease inhibitors
Number of subjects: 19
Study 8021437 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 10-30 mg
Number of subjects: 472
Study 8021437 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20-60 mg
Number of subjects: 472
Study 8021437 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 50-150 mg
Number of subjects: 472
Study 2563985 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 94
Study 2563985 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 94
Study 2563985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 31805822 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of adjustment
Number of subjects: 59
Study 31805822 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-alternative forced-choice (2AFC) method
Number of subjects: 59
Study 31805822 — intervention group
Group type: EXPERIMENTAL
Intervention: Likeness rating (LR)
Number of subjects: 59
Study 28782109 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion triggered by hb < 8 g/dl
Number of subjects: 58
Study 28782109 — intervention group
Group type: COMPARATOR
Intervention: RBC transfusion triggered by hb < 9.7 g/dl
Number of subjects: 58
Study 24141892 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ≥18 years (n = 40)
Number of subjects: 49
Study 24141892 — intervention group
Group type: COMPARATOR
Intervention: Group <18 years (n = 9)
Number of subjects: 49
Study 23238884 — intervention group
Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) technique
Number of subjects: 65
Study 23238884 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 65
Study 21572152 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg, 80 mg, or 120 mg daily
Number of subjects: 153
Study 21572152 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (any dose)
Number of subjects: 153
Study 21572152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 17925336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg every day)
Number of subjects: 306
Study 17925336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 17183893 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional trials from 1974-1978
Number of subjects: 821
Study 17183893 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials from 1974-1978
Number of subjects: 821
Study 17183893 — intervention group
Group type: COMPARATOR
Intervention: Animal/laboratory articles
Number of subjects: 821
Study 17183893 — intervention group
Group type: COMPARATOR
Intervention: Review articles
Number of subjects: 821
Study 17183893 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive trials
Number of subjects: 821
Study 17183893 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled clinical trials
Number of subjects: 821
Study 17183893 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized controlled trials
Number of subjects: 821
Study 17183893 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventional trials criteria
Number of subjects: 821
Study 14680343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42448
Study 14680343 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 42448
Study 14680343 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 42448
Study 14680343 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 42448
Study 14680343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 42448
Study 14680343 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42448
Study 10750626 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet (ED)
Number of subjects: 91
Study 10750626 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 91
Study 10750626 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 91
Study 10750626 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 91
Study 8881623 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 20
Study 8881623 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (ET)
Number of subjects: 20
Study 8097102 — intervention group
Group type: EXPERIMENTAL
Intervention: ebastine (20 mg)
Number of subjects: 12
Study 8097102 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (15 mg)
Number of subjects: 12
Study 8097102 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 3746897 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological group
Number of subjects: 51
Study 3746897 — intervention group
Group type: COMPARATOR
Intervention: Biological cause group
Number of subjects: 51
Study 3746897 — intervention group
Group type: COMPARATOR
Intervention: No information group
Number of subjects: 51
Study 3746897 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study 29559597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated water bath and ozonated oil topical application once a day for 4 weeks
Number of subjects: 60
Study 29559597 — intervention group
Group type: COMPARATOR
Intervention: Naftifine hydrochloride and ketoconazole cream once a day for 4 weeks
Number of subjects: 60
Study 26927237 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly use of ibuprofen
Number of subjects: 11795
Study 26927237 — intervention group
Group type: COMPARATOR
Intervention: Puberty onset after 15 years of age
Number of subjects: 11795
Study 26927237 — intervention group
Group type: COMPARATOR
Intervention: Vitamin use
Number of subjects: 11795
Study 24631057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 24631057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 2 mg
Number of subjects: 128
Study 24631057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 128
Study 24631057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 128
Study 22588047 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR; containing ∼5.0 mmol of nitrate)
Number of subjects: 12
Study 20179901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive supervised pelvic floor muscle training (PFMT)
Number of subjects: 62
Study 20179901 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised pelvic floor muscle training (PFMT)
Number of subjects: 62
Study 18391640 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 37
Study 18391640 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training + Aerobic Exercise (ST+AE)
Number of subjects: 37
Study 18391640 — intervention group
Group type: COMPARATOR
Intervention: Stretching Exercises (Control)
Number of subjects: 37
Study 18391640 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vasoconstrictor hormones
Number of subjects: 37
Study 18391640 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery vasoreactivity
Number of subjects: 37
Study 15798044 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment to lower intraocular pressure
Number of subjects: 2
Study 15798044 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2
Study 12213354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate hydrochloride (5‐HT(A2) receptor antagonist)
Number of subjects: 10
Study 12213354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 10
Study 10626097 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa-benserazide dispersible formulation
Number of subjects: 8
Study 10626097 — intervention group
Group type: COMPARATOR
Intervention: standard form
Number of subjects: 8
Study 7854533 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic patients
Number of subjects: 56
Study 7854533 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy volunteers
Number of subjects: 56
Study 1659253 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg/kg)
Number of subjects: 4
Study 1659253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 micrograms/kg)
Number of subjects: 4
Study 1659253 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.3 mg/kg)
Number of subjects: 4
Study 1659253 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 4
Study 6101843 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 203
Study 6101843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 31364872 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study 28363322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 55
Study 28363322 — intervention group
Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 55
Study 26692178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-wide training intervention on long-acting reversible contraception
Number of subjects: 648
Study 26692178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 648
Study 26692178 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health insurance
Number of subjects: 648
Study 26692178 — intervention group
Group type: EXPERIMENTAL
Intervention: State Medicaid enrollees abortion coverage
Number of subjects: 648
Study 26692178 — intervention group
Group type: EXPERIMENTAL
Intervention: State mandates for private health insurance to cover contraception
Number of subjects: 648
Study 26692178 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance used to pay for abortion
Number of subjects: 648
Study 24395492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment using various pain scales and questionnaires
Number of subjects: 49
Study 24395492 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal threshold testing for cold and warm detection
Number of subjects: 49
Study 21541030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-temperature meat diet with inhibitors (cruciferous vegetables, yogurt, chlorophyllin tablets)
Number of subjects: 16
Study 21541030 — intervention group
Group type: COMPARATOR
Intervention: High-temperature meat diet
Number of subjects: 16
Study 21541030 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitor diet
Number of subjects: 16
Study 21541030 — intervention group
Group type: COMPARATOR
Intervention: Low-temperature meat diet
Number of subjects: 16
Study 19010741 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 59
Study 19010741 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (100 microg)
Number of subjects: 59
Study 19010741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59